InvestorsHub Logo
Followers 32
Posts 3238
Boards Moderated 0
Alias Born 08/31/2006

Re: None

Wednesday, 07/06/2016 10:04:49 AM

Wednesday, July 06, 2016 10:04:49 AM

Post# of 5644
Xoma Corporate Presentation July 2016
http://www.xoma.com/pdf/XOMACorporatePresentation-July2016.pdf

Financial Highlights

$46.2M cash at March 31, 2016
Cash runway through at least first quarter of 2017
~ 120M shares outstanding at March 31, 2016
Significant partnerships advancing non-endocrine
assets

Value Created Through Partnerships

Novartis anti-CD40 Antibody (CFZ533) Program
• Five ongoing clinical studies
• Milestones received; tiered high-single to lower mid-teen digit royalties
Novartis TGFß Antibody Program – October 2015
• $480M potential milestones; tiered mid-single to low-double digit royalties
Novo Nordisk XMetA Antibody Program – December 2015
• Selective insulin receptor up regulator for diabetes
• $290M potential milestones; tiered mid- to high-single digit royalties
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent XOMA News